Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 558

1.

Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.

Benajiba L, Alexe G, Su A, Raffoux E, Soulier J, Hemann MT, Hermine O, Itzykson R, Stegmaier K, Puissant A.

Leukemia. 2018 Nov 2. doi: 10.1038/s41375-018-0291-x. [Epub ahead of print] No abstract available.

PMID:
30390009
2.

Imaging Artificial Membranes Using High-Speed Atomic Force Microscopy.

Nasrallah H, Vial A, Pocholle N, Soulier J, Costa L, Godefroy C, Bourillot E, Lesniewska E, Milhiet PE.

Methods Mol Biol. 2019;1886:45-59. doi: 10.1007/978-1-4939-8894-5_3.

PMID:
30374861
3.

Deletion 6q drives T-cell leukemia progression by ribosome modulation.

Gachet S, El-Chaar T, Avran D, Genescà E, Catez F, Quentin S, Delord M, Thérizols G, Briot D, Meunier G, Hernandez L, Pla M, Smits WK, Buijs-Gladdines JGCAM, Van Loocke W, Menschaert G, André-Schmutz I, Taghon T, Van Vlierberghe P, Meijerink JP, Baruchel A, Dombret H, Clappier E, Diaz JJ, Gazin C, de The H, Sigaux F, Soulier J.

Cancer Discov. 2018 Sep 28. pii: CD-17-0831. doi: 10.1158/2159-8290.CD-17-0831. [Epub ahead of print]

PMID:
30266814
4.

A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing.

Verboom K, Van Loocke W, Volders PJ, Decaesteker B, Avila Cobos F, Bornschein S, de Bock CE, Kalender Atak Z, Clappier E, Aerts S, Cools J, Soulier J, Taghon T, Van Vlierberghe P, Vandesompele J, Speleman F, Durinck K.

Haematologica. 2018 Jun 28. pii: haematol.2018.190587. doi: 10.3324/haematol.2018.190587. [Epub ahead of print] No abstract available.

5.

Structure-activity relationships of β-hairpin mimics as modulators of amyloid β-peptide aggregation.

Tonali N, Kaffy J, Soulier JL, Gelmi ML, Erba E, Taverna M, van Heijenoort C, Ha-Duong T, Ongeri S.

Eur J Med Chem. 2018 Jun 25;154:280-293. doi: 10.1016/j.ejmech.2018.05.018. Epub 2018 May 18.

PMID:
29807333
6.

The use of 4,4,4-trifluorothreonine to stabilize extended peptide structures and mimic β-strands.

Xu Y, Correia I, Ha-Duong T, Kihal N, Soulier JL, Kaffy J, Crousse B, Lequin O, Ongeri S.

Beilstein J Org Chem. 2017 Dec 21;13:2842-2853. doi: 10.3762/bjoc.13.276. eCollection 2017.

7.

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.

Ali A, Penneroux J, Dal Bello R Jr, Massé A, Quentin S, Unnikrishnan A, Hernandez L, Raffoux E, Ben Abdelali R, Renneville A, Preudhomme C, Pimanda J, Dombret H, Soulier J, Fenaux P, Clappier E, Adès L, Puissant A, Itzykson R.

Leukemia. 2018 Aug;32(8):1856-1860. doi: 10.1038/s41375-018-0076-2. Epub 2018 Feb 26. No abstract available.

PMID:
29535430
8.

HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.

de Bock CE, Demeyer S, Degryse S, Verbeke D, Sweron B, Gielen O, Vandepoel R, Vicente C, Vanden Bempt M, Dagklis A, Geerdens E, Bornschein S, Gijsbers R, Soulier J, Meijerink JP, Heinäniemi M, Teppo S, Bouvy-Liivrand M, Lohi O, Radaelli E, Cools J.

Cancer Discov. 2018 May;8(5):616-631. doi: 10.1158/2159-8290.CD-17-0583. Epub 2018 Mar 1.

PMID:
29496663
9.

Reduced recruitment of 53BP1 during interstrand crosslink repair is associated with genetically inherited attenuation of mitomycin C sensitivity in a family with Fanconi anemia.

Lesport E, Ferster A, Biver A, Roch B, Vasquez N, Jabado N, Vives FL, Revy P, Soulier J, de Villartay JP.

Oncotarget. 2017 Dec 17;9(3):3779-3793. doi: 10.18632/oncotarget.23375. eCollection 2018 Jan 9.

10.

Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia.

Reina-Castillón J, Pujol R, López-Sánchez M, Rodríguez-Santiago B, Aza-Carmona M, González JR, Casado JA, Bueren JA, Sevilla J, Badel I, Català A, Beléndez C, Dasí MÁ, Díaz de Heredia C, Soulier J, Schindler D, Pérez-Jurado LA, Surrallés J.

Blood Adv. 2017 Jan 23;1(5):319-329. doi: 10.1182/bloodadvances.2016000943. eCollection 2017 Jan 24. Erratum in: Blood Adv. 2017 Jul 31;1(18):1368.

11.

Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

Degryse S, Bornschein S, de Bock CE, Leroy E, Vanden Bempt M, Demeyer S, Jacobs K, Geerdens E, Gielen O, Soulier J, Harrison CJ, Constantinescu SN, Cools J.

Blood. 2018 Jan 25;131(4):421-425. doi: 10.1182/blood-2017-07-797597. Epub 2017 Nov 29.

12.

A landscape of germ line mutations in a cohort of inherited bone marrow failure patients.

Bluteau O, Sebert M, Leblanc T, Peffault de Latour R, Quentin S, Lainey E, Hernandez L, Dalle JH, Sicre de Fontbrune F, Lengline E, Itzykson R, Clappier E, Boissel N, Vasquez N, Da Costa M, Masliah-Planchon J, Cuccuini W, Raimbault A, De Jaegere L, Adès L, Fenaux P, Maury S, Schmitt C, Muller M, Domenech C, Blin N, Bruno B, Pellier I, Hunault M, Blanche S, Petit A, Leverger G, Michel G, Bertrand Y, Baruchel A, Socié G, Soulier J.

Blood. 2018 Feb 15;131(7):717-732. doi: 10.1182/blood-2017-09-806489. Epub 2017 Nov 16.

PMID:
29146883
13.

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.

Petit A, Trinquand A, Chevret S, Ballerini P, Cayuela JM, Grardel N, Touzart A, Brethon B, Lapillonne H, Schmitt C, Thouvenin S, Michel G, Preudhomme C, Soulier J, Landman-Parker J, Leverger G, Macintyre E, Baruchel A, Asnafi V; French Acute Lymphoblastic Leukemia Study Group (FRALLE).

Blood. 2018 Jan 18;131(3):289-300. doi: 10.1182/blood-2017-04-778829. Epub 2017 Oct 19.

PMID:
29051182
14.

Biallelic truncating FANCM mutations cause early-onset cancer but not Fanconi anemia.

Bogliolo M, Bluteau D, Lespinasse J, Pujol R, Vasquez N, d'Enghien CD, Stoppa-Lyonnet D, Leblanc T, Soulier J, Surrallés J.

Genet Med. 2018 Apr;20(4):458-463. doi: 10.1038/gim.2017.124. Epub 2017 Aug 24.

PMID:
28837157
15.

Biallelic inactivation of REV7 is associated with Fanconi anemia.

Bluteau D, Masliah-Planchon J, Clairmont C, Rousseau A, Ceccaldi R, d'Enghien CD, Bluteau O, Cuccuini W, Gachet S, de Latour RP, Leblanc T, Socié G, Baruchel A, Stoppa-Lyonnet D, D'Andrea AD, Soulier J.

J Clin Invest. 2017 Mar 1;127(3):1117. doi: 10.1172/JCI92946. Epub 2017 Mar 1. No abstract available.

16.

Introduction to the review series on T-cell malignancies.

Sehn LH, Soulier J.

Blood. 2017 Mar 2;129(9):1059-1060. doi: 10.1182/blood-2017-01-741389. Epub 2017 Jan 23. No abstract available.

17.

dUTPase (DUT) Is Mutated in a Novel Monogenic Syndrome With Diabetes and Bone Marrow Failure.

Dos Santos RS, Daures M, Philippi A, Romero S, Marselli L, Marchetti P, Senée V, Bacq D, Besse C, Baz B, Marroquí L, Ivanoff S, Masliah-Planchon J, Nicolino M, Soulier J, Socié G, Eizirik DL, Gautier JF, Julier C.

Diabetes. 2017 Apr;66(4):1086-1096. doi: 10.2337/db16-0839. Epub 2017 Jan 10.

18.

Extended clinical and genetic spectrum associated with biallelic RTEL1 mutations.

Touzot F, Kermasson L, Jullien L, Moshous D, Ménard C, Ikincioğullari A, Doğu F, Sari S, Giacobbi-Milet V, Etzioni A, Soulier J, Londono-Vallejo A, Fischer A, Callebaut I, de Villartay JP, Leblanc T, Kannengiesser C, Revy P.

Blood Adv. 2016 Nov 22;1(1):36-46. doi: 10.1182/bloodadvances.2016001313. eCollection 2016 Nov 29.

19.

Copy-number analysis identified new prognostic marker in acute myeloid leukemia.

Nibourel O, Guihard S, Roumier C, Pottier N, Terre C, Paquet A, Peyrouze P, Geffroy S, Quentin S, Alberdi A, Abdelali RB, Renneville A, Demay C, Celli-Lebras K, Barbry P, Quesnel B, Castaigne S, Dombret H, Soulier J, Preudhomme C, Cheok MH.

Leukemia. 2017 Mar;31(3):555-564. doi: 10.1038/leu.2016.265. Epub 2016 Sep 30.

PMID:
27686867
20.

Biallelic inactivation of REV7 is associated with Fanconi anemia.

Bluteau D, Masliah-Planchon J, Clairmont C, Rousseau A, Ceccaldi R, Dubois d'Enghien C, Bluteau O, Cuccuini W, Gachet S, Peffault de Latour R, Leblanc T, Socié G, Baruchel A, Stoppa-Lyonnet D, D'Andrea AD, Soulier J.

J Clin Invest. 2016 Sep 1;126(9):3580-4. doi: 10.1172/JCI88010. Epub 2016 Aug 8. Erratum in: J Clin Invest. 2017 Mar 1;127(3):1117.

21.

Speed of leukemia development and genetic diversity in xenograft models of T cell acute lymphoblastic leukemia.

Poglio S, Lewandowski D, Calvo J, Caye A, Gros A, Laharanne E, Leblanc T, Landman-Parker J, Baruchel A, Soulier J, Ballerini P, Clappier E, Pflumio F.

Oncotarget. 2016 Jul 5;7(27):41599-41611. doi: 10.18632/oncotarget.9313.

22.

A nonsense mutation in the DNA repair factor Hebo causes mild bone marrow failure and microcephaly.

Zhang S, Pondarre C, Pennarun G, Labussiere-Wallet H, Vera G, France B, Chansel M, Rouvet I, Revy P, Lopez B, Soulier J, Bertrand P, Callebaut I, de Villartay JP.

J Exp Med. 2016 May 30;213(6):1011-28. doi: 10.1084/jem.20151183. Epub 2016 May 16.

23.

Long noncoding RNA signatures define oncogenic subtypes in T-cell acute lymphoblastic leukemia.

Wallaert A, Durinck K, Van Loocke W, Van de Walle I, Matthijssens F, Volders PJ, Avila Cobos F, Rombaut D, Rondou P, Mestdagh P, Vandesompele J, Poppe B, Taghon T, Soulier J, Van Vlierberghe P, Speleman F.

Leukemia. 2016 Sep;30(9):1927-30. doi: 10.1038/leu.2016.82. Epub 2016 Apr 22. No abstract available.

PMID:
27168467
24.

TGF-β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia.

Zhang H, Kozono DE, O'Connor KW, Vidal-Cardenas S, Rousseau A, Hamilton A, Moreau L, Gaudiano EF, Greenberger J, Bagby G, Soulier J, Grompe M, Parmar K, D'Andrea AD.

Cell Stem Cell. 2016 May 5;18(5):668-81. doi: 10.1016/j.stem.2016.03.002. Epub 2016 Mar 24.

25.

How I treat MDS and AML in Fanconi anemia.

Peffault de Latour R, Soulier J.

Blood. 2016 Jun 16;127(24):2971-9. doi: 10.1182/blood-2016-01-583625. Epub 2016 Mar 28.

26.

MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children's Oncology Group Study.

Matlawska-Wasowska K, Kang H, Devidas M, Wen J, Harvey RC, Nickl CK, Ness SA, Rusch M, Li Y, Onozawa M, Martinez C, Wood BL, Asselin BL, Chen IM, Roberts KG, Baruchel A, Soulier J, Dombret H, Zhang J, Larson RS, Raetz EA, Carroll WL, Winick NJ, Aplan PD, Loh ML, Mullighan CG, Hunger SP, Heerema NA, Carroll AJ, Dunsmore KP, Winter SS.

Leukemia. 2016 Sep;30(9):1909-12. doi: 10.1038/leu.2016.60. Epub 2016 Mar 8. No abstract available.

27.

Mutations of the RTEL1 Helicase in a Hoyeraal-Hreidarsson Syndrome Patient Highlight the Importance of the ARCH Domain.

Jullien L, Kannengiesser C, Kermasson L, Cormier-Daire V, Leblanc T, Soulier J, Londono-Vallejo A, de Villartay JP, Callebaut I, Revy P.

Hum Mutat. 2016 May;37(5):469-72. doi: 10.1002/humu.22966. Epub 2016 Feb 23.

PMID:
26847928
28.

Designed Glycopeptidomimetics Disrupt Protein-Protein Interactions Mediating Amyloid β-Peptide Aggregation and Restore Neuroblastoma Cell Viability.

Kaffy J, Brinet D, Soulier JL, Correia I, Tonali N, Fera KF, Iacone Y, Hoffmann AR, Khemtémourian L, Crousse B, Taylor M, Allsop D, Taverna M, Lequin O, Ongeri S.

J Med Chem. 2016 Mar 10;59(5):2025-40. doi: 10.1021/acs.jmedchem.5b01629. Epub 2016 Feb 4.

PMID:
26789783
29.

Noninvasive molecular screening for oral precancer in Fanconi anemia patients.

Smetsers SE, Velleuer E, Dietrich R, Wu T, Brink A, Buijze M, Deeg DJ, Soulier J, Leemans CR, Braakhuis BJ, Brakenhoff RH.

Cancer Prev Res (Phila). 2015 Nov;8(11):1102-11. doi: 10.1158/1940-6207.CAPR-15-0220. Epub 2015 Aug 14.

30.

An in vivo genetic reversion highlights the crucial role of Myb-Like, SWIRM, and MPN domains 1 (MYSM1) in human hematopoiesis and lymphocyte differentiation.

Le Guen T, Touzot F, André-Schmutz I, Lagresle-Peyrou C, France B, Kermasson L, Lambert N, Picard C, Nitschke P, Carpentier W, Bole-Feysot C, Lim A, Cavazzana M, Callebaut I, Soulier J, Jabado N, Fischer A, de Villartay JP, Revy P.

J Allergy Clin Immunol. 2015 Dec;136(6):1619-1626.e5. doi: 10.1016/j.jaci.2015.06.008. Epub 2015 Jul 26.

PMID:
26220525
31.

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.

Lazareth A, Song XY, Coquin A, Harel S, Karlin L, Belhadj K, Roos-Weil D, Frenzel L, Tamburini J, Macro M, Chevret S, Loiseau HA, Minvielle S, Fermand JP, Soulier J, Bories JC, Arnulf B.

Haematologica. 2015 Nov;100(11):e471-4. doi: 10.3324/haematol.2015.127001. Epub 2015 Jul 23. No abstract available.

32.

Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.

Vicente C, Schwab C, Broux M, Geerdens E, Degryse S, Demeyer S, Lahortiga I, Elliott A, Chilton L, La Starza R, Mecucci C, Vandenberghe P, Goulden N, Vora A, Moorman AV, Soulier J, Harrison CJ, Clappier E, Cools J.

Haematologica. 2015 Oct;100(10):1301-10. doi: 10.3324/haematol.2015.130179. Epub 2015 Jul 23.

33.

Distinctive genotypes in infants with T-cell acute lymphoblastic leukaemia.

Mansur MB, van Delft FW, Colman SM, Furness CL, Gibson J, Emerenciano M, Kempski H, Clappier E, Cave H, Soulier J, Pombo-de-Oliveira MS, Greaves M, Ford AM.

Br J Haematol. 2015 Nov;171(4):574-84. doi: 10.1111/bjh.13613. Epub 2015 Jul 24.

34.

Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia.

Durinck K, Van Loocke W, Van der Meulen J, Van de Walle I, Ongenaert M, Rondou P, Wallaert A, de Bock CE, Van Roy N, Poppe B, Cools J, Soulier J, Taghon T, Speleman F, Van Vlierberghe P.

Leukemia. 2015 Dec;29(12):2317-27. doi: 10.1038/leu.2015.162. Epub 2015 Jun 25.

PMID:
26108691
35.

Introduction to the review series on acute lymphoblastic leukemia.

Soulier J, Cortes J.

Blood. 2015 Jun 25;125(26):3965-6. doi: 10.1182/blood-2015-05-635300. Epub 2015 May 21. No abstract available.

36.

HLA-matched related-donor HSCT in Fanconi anemia patients conditioned with cyclophosphamide and fludarabine.

Benajiba L, Salvado C, Dalle JH, Jubert C, Galambrun C, Soulier J, Socié G, Peffault de Latour R.

Blood. 2015 Jan 8;125(2):417-8. doi: 10.1182/blood-2014-10-605113. No abstract available.

37.

ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling.

Goossens S, Radaelli E, Blanchet O, Durinck K, Van der Meulen J, Peirs S, Taghon T, Tremblay CS, Costa M, Farhang Ghahremani M, De Medts J, Bartunkova S, Haigh K, Schwab C, Farla N, Pieters T, Matthijssens F, Van Roy N, Best JA, Deswarte K, Bogaert P, Carmichael C, Rickard A, Suryani S, Bracken LS, Alserihi R, Canté-Barrett K, Haenebalcke L, Clappier E, Rondou P, Slowicka K, Huylebroeck D, Goldrath AW, Janzen V, McCormack MP, Lock RB, Curtis DJ, Harrison C, Berx G, Speleman F, Meijerink JP, Soulier J, Van Vlierberghe P, Haigh JJ.

Nat Commun. 2015 Jan 7;6:5794. doi: 10.1038/ncomms6794.

38.

Comparing genotoxic signatures in cord blood cells from neonates exposed in utero to zidovudine or tenofovir.

Vivanti A, Soheili TS, Cuccuini W, Luce S, Mandelbrot L, Lechenadec J, Cordier AG, Azria E, Soulier J, Cavazzana M, Blanche S, André-Schmutz I.

AIDS. 2015 Jul 17;29(11):1319-24. doi: 10.1097/QAD.0000000000000564.

39.

Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in non-Hodgkin lymphoma.

Guenat D, Quentin S, Rizzari C, Lundin C, Coliva T, Edery P, Fryssira H, Bermont L, Ferrand C, Soulier J, Borg C, Rohrlich PS.

J Hematol Oncol. 2014 Nov 7;7:82. doi: 10.1186/s13045-014-0082-4.

40.

Fanconi anemia and solid malignancies in childhood: a national retrospective study.

Malric A, Defachelles AS, Leblanc T, Lescoeur B, Lacour B, Peuchmaur M, Maurage CA, Pierron G, Guillemot D, d'Enghien CD, Soulier J, Stoppa-Lyonnet D, Bourdeaut F.

Pediatr Blood Cancer. 2015 Mar;62(3):463-70. doi: 10.1002/pbc.25303. Epub 2014 Nov 8.

PMID:
25381700
41.

A novel tumor suppressor function of Kindlin-3 in solid cancer.

Djaafri I, Khayati F, Menashi S, Tost J, Podgorniak MP, Sadoux A, Daunay A, Teixeira L, Soulier J, Idbaih A, Setterblad N, Fauvel F, Calvo F, Janin A, Lebbé C, Mourah S.

Oncotarget. 2014 Oct 15;5(19):8970-85.

42.

The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.

Durinck K, Wallaert A, Van de Walle I, Van Loocke W, Volders PJ, Vanhauwaert S, Geerdens E, Benoit Y, Van Roy N, Poppe B, Soulier J, Cools J, Mestdagh P, Vandesompele J, Rondou P, Van Vlierberghe P, Taghon T, Speleman F.

Haematologica. 2014 Dec;99(12):1808-16. doi: 10.3324/haematol.2014.115683. Epub 2014 Oct 24.

43.

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.

Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E, Lammens T, De Moerloose B, Benoit Y, Poppe B, Meijerink JP, Cools J, Soulier J, Rabbitts TH, Taghon T, Speleman F, Van Vlierberghe P.

Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9.

44.

When old hematopoietic stem cells get damaged.

Soulier J.

Cell Stem Cell. 2014 Oct 2;15(4):399-400. doi: 10.1016/j.stem.2014.09.012.

45.

Structure-activity relationships of sugar-based peptidomimetics as modulators of amyloid β-peptide early oligomerization and fibrillization.

Kaffy J, Brinet D, Soulier JL, Khemtémourian L, Lequin O, Taverna M, Crousse B, Ongeri S.

Eur J Med Chem. 2014 Oct 30;86:752-8. doi: 10.1016/j.ejmech.2014.09.031. Epub 2014 Sep 10.

PMID:
25238173
46.

MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia.

Mets E, Van der Meulen J, Van Peer G, Boice M, Mestdagh P, Van de Walle I, Lammens T, Goossens S, De Moerloose B, Benoit Y, Van Roy N, Clappier E, Poppe B, Vandesompele J, Wendel HG, Taghon T, Rondou P, Soulier J, Van Vlierberghe P, Speleman F.

Leukemia. 2015 Apr;29(4):798-806. doi: 10.1038/leu.2014.276. Epub 2014 Sep 18.

47.

A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.

Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, Xu L, Castillo-Martin M, Llobet-Navás D, Cordon-Cardo C, Clappier E, Soulier J, Ferrando AA.

Nat Med. 2014 Oct;20(10):1130-7. doi: 10.1038/nm.3665. Epub 2014 Sep 7.

48.

Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia.

Talbot A, Peffault de Latour R, Raffoux E, Buchbinder N, Vigouroux S, Milpied N, Leblanc T, Soulier J, Michallet M, Socié G.

Haematologica. 2014 Oct;99(10):e199-200. doi: 10.3324/haematol.2013.098954. Epub 2014 Aug 1. No abstract available.

49.

High frequency of exon 15 deletion in the FANCA gene in Tunisian patients affected with Fanconi anemia disease: implication for diagnosis.

Amouri A, Talmoudi F, Messaoud O, d'Enghien CD, Rekaya MB, Allegui I, Azaiez H, Kefi R, Abdelhak A, Meseddi SH, Torjemane L, Ouederni M, Mellouli F, Abid HB, Aissaoui L, Bejaoui M, Othmen TB, Lyonnet DS, Soulier J, Hachicha M, Dellagi K, Abdelhak S, Fanconi T.

Mol Genet Genomic Med. 2014 Mar;2(2):160-5. doi: 10.1002/mgg3.55. Epub 2014 Feb 5.

50.

Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.

Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E.

Haematologica. 2013 Nov;98(11):e146-8. doi: 10.3324/haematol.2013.095372. No abstract available.

Supplemental Content

Loading ...
Support Center